Mira Pharmaceuticals Stock Price Target by the Numbers: A Data Analysis for Investors
The mira pharmaceuticals stock price target is one of the harder analytical problems in small-cap biotech. MIRA is a pre-revenue clinical-stage company, which means traditional earnings-based valuation models break down immediately. You cannot run a straightforward P/E analysis on a company with no earnings. What you can do is build a probability-weighted scenario model, examine the pipeline assets, study the cash burn rate, and apply a margin of safety that reflects how often early-stage drug candidates fail to reach commercialization. That is exactly what this analysis does.
Mira Pharmaceuticals (Nasdaq: MIRA) is a small biopharmaceutical company focused on neurological and psychiatric indications, including anxiety and cognitive disorders. As of early 2026 the stock trades in the low single digits with a market capitalization under $50 million. Analyst coverage is thin, institutional ownership is minimal, and the stock is driven almost entirely by clinical news flow.
Key Takeaways
- MIRA is a pre-revenue clinical-stage company; traditional price-to-earnings analysis does not apply.
- The company's pipeline centers on synthetic cannabinoid derivatives with potential in anxiety, neuropathic pain, and cognitive disorders.
- Any rational mira pharmaceuticals stock price target must be built on probability-weighted cash flow scenarios, not extrapolated earnings.
- Cash burn and runway are the most important near-term metrics; a secondary offering risk is real.
- The EV/FCF and EV/EBITDA multiples used for commercial-stage biotech are inapplicable here; margin of safety comes from cash position relative to market cap.
- Small-cap clinical biotech carries binary outcome risk; position sizing matters as much as the price target itself.
Why Standard Valuation Models Do Not Work for MIRA
Most investors who search for the mira pharmaceuticals stock price target are hoping for a number derived from earnings, revenue, or cash flow. MIRA has none of those yet.
In Q3 2025 the company reported a net loss of approximately $2.1 million on zero revenue, which is typical for a clinical-stage company funding trials through equity issuances. The balance sheet showed roughly $8 million in cash, which at the current burn rate represents about 12 to 18 months of runway.
Traditional metrics like EV/EBITDA or EV/FCF are meaningless here because both the denominator and the resulting ratio are negative or undefined. What matters instead is:
- How much cash does the company have versus how much it needs to reach a catalyst?
- What is the probability that the lead candidate succeeds in trials?
- What is the commercial value of the asset if it succeeds?
- What discount rate reflects the risk of failure?
The Pipeline: What MIRA Is Actually Betting On
MIRA's lead program is KLS-13019, a synthetic analog of cannabidiol designed to address neuropathic pain and anxiety with a cleaner pharmacological profile than natural cannabinoids. The company has also disclosed early work on analogs targeting cognitive enhancement.
The clinical landscape for cannabinoid-based neurological treatments is genuinely competitive. GW Pharmaceuticals (now part of Jazz Pharmaceuticals) established proof-of-concept for synthetic cannabinoid drugs with Epidiolex. MIRA's differentiation argument is that KLS-13019 offers improved selectivity, potentially reducing side effects that have limited other cannabinoid therapies.
Phase 1 data, if it shows a clean safety profile, is the first meaningful catalyst. Phase 2 efficacy data is the inflection point that determines whether the asset has real commercial value. Neither timeline is certain.
Building a Scenario-Based Price Target for MIRA
Because MIRA has no revenue, the only intellectually honest approach to a mira pharmaceuticals stock price target is a probability-weighted scenario analysis. We modeled three outcomes.
| Scenario | Probability | Description | Estimated Equity Value | Per-Share Estimate |
|---|---|---|---|---|
| Bull (successful Phase 2, partnership deal) | 15% | KLS-13019 shows strong efficacy, MIRA signs a licensing deal worth $150-200M upfront | $180M market cap | $6.80-$8.20 |
| Base (mixed Phase 2, continues independently) | 35% | Partial efficacy signal, company continues trials with dilutive financing | $25-40M market cap | $0.90-$1.50 |
| Bear (trial failure or cash exhaustion) | 50% | Lead candidate fails, secondary offering at distressed prices, or operations wind down | $5-10M market cap | $0.10-$0.30 |
Weighted expected value across these three scenarios lands in a range of approximately $1.50 to $2.30 per share, which puts meaningful downside relative to most price points where the stock has traded in 2025.
That does not mean MIRA is uninvestable. It means the expected value calculation has to account for a 50% probability of near-total loss.
EV/FCF and Margin of Safety Applied to Clinical Biotech
The glossary metric that applies most directly to MIRA is margin of safety, not EV/FCF or EV/EBITDA. With roughly $8 million in cash and a market cap near $30-40 million, the cash covers about 20-25% of the enterprise value. That cash-to-market-cap ratio is the floor metric.
If MIRA were priced at or below its cash value, you would have a meaningful margin of safety because the downside is bounded by asset liquidation. At a premium of 3-4x cash, you are paying almost entirely for the pipeline optionality, with no asset-level protection.
Comparing MIRA to commercial-stage biotech using EV/EBITDA multiples, as some retail screeners do, produces a nonsense output. A company with negative EBITDA and a positive EV is not trading at a "negative multiple." It is trading on hopes about future cash flows, full stop.
Our DCF calculator lets you model exactly this scenario. You can input a probability-weighted revenue forecast for Year 5 or Year 7 (when commercialization might occur), apply a 25-35% discount rate appropriate for clinical-stage biotech, and back into a present value. The tool supports four DCF models, which is useful when you are trying to triangulate across different assumptions about success probability.
What Analyst Price Targets Are Actually Saying
When a sell-side analyst publishes a mira pharmaceuticals stock price target, they are almost always using a risk-adjusted NPV (rNPV) model. The analyst assigns probabilities to each stage of the clinical pipeline, projects peak sales if the drug reaches market, and discounts those cash flows back to present value at a discount rate that reflects clinical and commercial risk.
A $4.00 analyst target on MIRA does not mean the stock will reach $4.00. It means the analyst believes the probability-weighted present value of the pipeline is approximately $4.00 per share at current diluted share count, before additional dilution from future equity raises.
The critical variable most retail investors miss: share count. MIRA will almost certainly issue more shares to fund trials. If the company raises $15 million at $1.00 per share to fund a Phase 2 trial, that is 15 million new shares. If there are currently 28 million shares outstanding, the dilution is more than 50%. A $4.00 analyst target built on today's share count is worth roughly $2.60 after accounting for that dilution.
Red Flags and Risk Factors You Cannot Ignore
Clinical-stage biotech analysis requires a clear-eyed look at the downside. For MIRA specifically, four risks stand out.
First, cash runway. Twelve to eighteen months of runway at current burn means the company needs to either close a partnership deal, complete a successful equity raise, or reach a clinical milestone that justifies non-dilutive financing. None of these is guaranteed.
Second, trial design risk. A poorly designed Phase 2 trial can produce ambiguous results that neither confirm nor rule out efficacy. Ambiguous results often destroy small-cap biotech stocks because they delay the commercialization timeline without resolving the core uncertainty.
Third, regulatory risk. The FDA's position on cannabinoid-based therapeutics has evolved, but it remains complex. Novel scheduling considerations could complicate approval even if MIRA's clinical data is strong.
Fourth, competition. At least four other companies are working on synthetic cannabinoid analogs for neurological indications. If a larger, better-funded competitor advances first, MIRA's licensing use diminishes.
How to Use the Margin of Safety Metric When Screening Biotech
The margin of safety concept, developed by Benjamin Graham, works differently in clinical biotech than in industrial or consumer businesses. For a commercial company, margin of safety typically means buying at a price significantly below intrinsic value as calculated by discounted cash flows. For a pre-revenue biotech, it has two relevant applications.
The first application is the asset-floor margin of safety: how much of the market cap is covered by net cash? If a company has $8 million in cash and trades at a $12 million market cap, you are paying only $4 million for the pipeline optionality. That is a very different risk profile than paying $35 million for $8 million in cash.
The second application is position sizing as margin of safety. Because the binary outcome risk in clinical biotech is real, professional biotech investors rarely allocate more than 2-3% of portfolio value to a single pre-revenue name. The margin of safety is in the position size, not the price alone.
Further reading: SEC EDGAR · FRED Economic Data
Why MIRA stock analysis Matters
This section anchors the discussion on MIRA stock analysis. The detailed treatment, formula, and worked examples appear in the body of this article above. The points below summarize the most important takeaways for value investors who want to apply MIRA stock analysis in real portfolio decisions. ValueMarkers exposes the underlying data on every covered ticker via the screener and stock profile pages, so the concepts in this article translate directly into actionable filters.
Key inputs for MIRA stock analysis
See the main discussion of MIRA stock analysis in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using MIRA stock analysis alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Sector benchmarks for MIRA stock analysis
See the main discussion of MIRA stock analysis in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using MIRA stock analysis alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Related ValueMarkers Resources
- Enterprise Value to Free Cash Flow (EV/FCF) — Enterprise Value to Free Cash Flow captures how cheaply a stock trades relative to its fundamentals
- Enterprise Value to EBITDA (EV/EBITDA) — Enterprise Value to EBITDA is the metric used to how cheaply a stock trades relative to its fundamentals
- Margin of Safety — Margin of Safety expresses how cheaply a stock trades relative to its fundamentals
- Price Target Analysis Hub — related ValueMarkers analysis
- Stock Price Target Methodology — related ValueMarkers analysis
- Sandp 500 Futures — related ValueMarkers analysis
Frequently Asked Questions
what happens if the stock market crashes
A broad market crash affects clinical-stage biotech stocks significantly, but through a specific mechanism. When markets fall sharply, risk appetite collapses, and small-cap speculative names like MIRA typically fall harder than the index. The bigger practical risk is that a crash closes the equity capital markets. If MIRA needs to raise cash during a downturn, it may be forced to issue shares at a much lower price than it would in a stable market, compounding dilution for existing shareholders.
what time does the stock market open
U.S. stock markets, including Nasdaq where MIRA trades, open at 9:30 a.m. Eastern Time Monday through Friday. Pre-market trading begins at 4:00 a.m. Eastern on most brokerages. For a small-cap stock like MIRA, pre-market and after-hours liquidity is extremely thin, and bid-ask spreads can be very wide outside regular trading hours.
are stock markets closed today
U.S. stock markets are closed on weekends and on federal holidays including New Year's Day, Martin Luther King Jr. Day, Presidents' Day, Good Friday, Memorial Day, Juneteenth, Independence Day, Labor Day, Thanksgiving, and Christmas. The NYSE and Nasdaq both publish the official holiday schedule annually. If a holiday falls on a weekend, the market typically closes on the nearest weekday.
what time does the stock market close
U.S. stock markets close at 4:00 p.m. Eastern Time on regular trading days. After-hours trading continues on most brokerages until 8:00 p.m. Eastern. For MIRA specifically, the most meaningful price action often occurs at open or close when clinical news is released, since after-hours liquidity in micro-cap stocks is minimal.
when does the stock market open
The U.S. stock market opens at 9:30 a.m. Eastern Time. Extended-hours trading starts as early as 4:00 a.m. Eastern on many platforms. For investors tracking mira pharmaceuticals stock price target movements around clinical announcements, note that biotechs often halt trading before releasing major trial results, then reopen at a significantly different price.
why is the stock market down today
Market declines happen for many reasons: rising interest rates, inflation data, geopolitical events, earnings disappointments, or simply profit-taking after a rally. For a stock like MIRA, the reasons the broader market is down matter less than company-specific news. A negative Phase 1 result or a dilutive financing announcement will move MIRA far more than any macro event.
Run your own scenario model for MIRA and any other clinical-stage biotech using our DCF calculator. It supports probability-weighted cash flow inputs, custom discount rates, and four distinct valuation models so you can stress-test your assumptions before committing capital.
Written by Javier Sanz, Founder of ValueMarkers. Last updated April 2026.
Ready to find your next value investment?
ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.
Related tools: DCF Calculator · Methodology · Compare ValueMarkers
Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.